Lumida
/CBLL
⌘K
Ceribell Inc

Ceribell Inc

CBLL
$18.72USD↓-2.19%-0.42 today

MARKET CAP

710.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$18 – $19

52W RANGE

$11
$24

AI Summary

Stalk
Sell NowMedium

CBLL has broken below clearly established support with a bearish Support Failure pattern confirming distribution in a Stage 3 context. The medium-term bias is bearish, and short-term price rejection at the 9/21/50 EMA zone favors immediate sell. We will sell now on the breakdown below the declining EMA cluster, targeting continuation participation. Key risks include potential support at the 200 DMA and any reclaim of EMAs invalidating the bearish posture.

  • ↑Q1 2026 revenue rose 29% YoY to $26.5M
  • ↑Active hospital accounts grew to 680, just 3% penetrated
  • ↓Q1 net loss expanded to $19.7M, deepening annual deficits
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

CeriBell, Inc. (NASDAQ: CBLL) is a pioneering company in the neuromonitoring sector, specializing in advanced EEG systems designed for seizure management and delirium monitoring in acute care settings. The company is emerging as a leader with a growing market presence, focusing on significantly underpenetrated demographics, including pediatric and neonatal patients. With an emphasis on leveraging innovative technology and obtaining regulatory clearances to expand its product lines, CeriBell aims to establish its EEG solutions as the new standard of care within hospitals.

Bull says

  • ↑Q1 2026 revenue rose 29% YoY to $26.5M
  • ↑Active hospital accounts grew to 680, just 3% penetrated
  • ↑Pediatric and neonatal product launches expected to drive growth
  • ↑Gross margin sustained at ~88%, indicating operational efficiency
  • ↑Full-year revenue guidance of $112–116M for 2026 supports outlook
  • ↑Solid liquidity and dividend yield factors offer downside buffer

Bear says

  • ↓Q1 net loss expanded to $19.7M, deepening annual deficits
  • ↓Operating expenses surged 36% YoY to $43.9M, pressuring margins
  • ↓Negative earnings yield and weak profitability factors imply value trap
  • ↓Seasonal Q2–Q3 volume dips risk utilization and revenue streak
  • ↓Rising legal and patent costs will elevate G&A expenses
  • ↓Competitive threats may erode pricing power and account growth

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-14-2026neutral

Transcript signals

Bull points

  • Q1 was a strong quarter. We delivered revenue of $26.5 million, growing 29% year-over-year and 7% sequentially, driven by record headband utilization and our largest quarter of net new account additions.
  • We also delivered 87% growth margin and expect to maintain growth margin in the high 80s range throughout 2026.
  • We remain confident in our ability to increase the number of new ads in 2026 above the level seen in 2025.

Bear points

  • We were running at about $1 to $2 million a quarter before, and as we kind of move through the year and you've got the comparison period and adjusted EBITDA, you'll be able to track that. So Q1 was outsized. Q2 also will likely be higher. We're right in the kind of peak part of the action with depositions and upcoming trials. So I'd expect Q2 to be elevated, too, and then it'll start to moderate as you move later into 2026.
  • G&A is really where the IP expense came in. That was a detailed $5.6 million, higher than what we've seen in prior quarters. That's a result of the cadence of the lawsuit where we're right now in Q1 and Q2 really at the heaviest expense as we prepare for and go to trial.
  • Net loss was $19.7 million for the first quarter of 2026, or a loss of 52 cents per share, compared to a loss of $12.8 million, or a loss of 36 cents per share in the first quarter of 2025.
Read full transcript analysis ›